A Phase 3 interventional study of pregabalin and placebo in Generalized Anxiety Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 68 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-10.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 48th largest by enrollment of the 234 interventional ones that give a count, is one of 13 that started in 2006, is one of 45 in phase 3, and was the 38th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
BTL Industries Ltd. · Sites in United States
Ages 22+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 53 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 51 · Phase 4 28
First in 1991; this study’s year is marked. 13 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 356 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 90 across the 234 interventional studies, 220 across the 28 observational. Of the 199 that completed or were terminated, 90 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 265 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 3 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
20 of the studies in Generalized Anxiety Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123467Phase 3Wayne State UniversityCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 2027-08-31 |
| NCT06846320AbbVieStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | 2026-11 |
| NCT06723158Boston UniversityOral Surgery Virtual Reality Glasses Study | 2026-12 |
| NCT04557891University of California, Los AngelesLow-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD). Efficacy will be measured by the improvement in the total Hamilton Anxiety Rating Scale (HAM-A) scores from baseline observed following 8 weeks of double-blind treatment or at earlier termination during the double-blind treatment phase and analyzed using a mixed linear model for repeated measures.
Further enrollment in this study was stopped on January 28, 2008 based on the recommendation of an independent data monitoring committee. The recommendation to stop the study was not based on any safety findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo
Drug: pregabalin
pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
Also known as: Lyrica
placebo + concurrent GAD treatment from the open-label study period
Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores
Change from baseline: average across visit weeks using mixed model. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety.
Time frame: Baseline, 8 weeks
Change in HAM-A Total Score at Weekly Visits
Change: score at each study week minus score at baseline. HAM-A, a clinician-rated interview, measures presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety.
Time frame: Baseline, Weeks 1 through Week 8
Number of Responders Using Hamilton Anxiety Rating Scale (HAM-A)
Responders = YES if subjects achieved a \>= 50% decrease in HAM-A total score from Baseline to respective study week. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; higher score indicates greater anxiety.
Time frame: Weeks 1 through Week 8
Subjects in Remission Using Hamilton Anxiety Rating Scale (HAM-A) Total Score
Participant in remission defined as HAM-A total score of \<= 7. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges 0 - 56; higher score indicates greater anxiety.
Time frame: Week 1 through Week 8
Time to Onset of Sustained Hamilton Anxiety Rating Scale (HAM-A) Improvement
Time to sustained improvement was defined as time to 50% or greater reduction in HAM-A total score from Baseline, which was sustained for the remainder of the study. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; a higher score indicates greater anxiety.
Time frame: Week 8
Number of Responders Using Clinical Global Impression of Improvement (CGI-I) Score
Responders = YES using CGI-I if score indicated much improved or very much improved at the last study week. CGI-I is a clinician-rated instrument that measures change in subject's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Week 1 through Week 8
Clinical Global Impression of Severity (CGI-S) Score
CGI-S is a clinician-rated instrument measuring the severity of a subject's symptoms on a 7-point categorical scale. Scores range from 1 (not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill.
Time frame: Week 8
Change in Hamilton Depression Rating Scale (HAM-D) Total Score
Change: score at each study week minus score at baseline. HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, \& weight loss). Total score ranges from 0 to 52; higher scores indicate more depression.
Time frame: Weeks 1 through Week 8
The study was conducted in 55 centers in 8 countries (United States, Russian Federation, Czech Republic, Ukraine, Serbia, Hungary, Finland, and Estonia).
| Milestone | Pregabalin | Placebo |
|---|---|---|
| Started | 180 | 176 |
| Completed | 108 | 113 |
| Not completed | 72 | 63 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Laboratory abnormality | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 7 | 2 |
| Withdrew: Due to termination of the study | 54 | 52 |
Change from baseline: average across visit weeks using mixed model. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety.
| score on scale | Pregabalin | Placebo |
|---|---|---|
| Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores | -7.6 ± 0.35 | -6.4 ± 0.36 |
Change: score at each study week minus score at baseline. HAM-A, a clinician-rated interview, measures presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety.
| score on scale | Pregabalin | Placebo |
|---|---|---|
| Week 1 (n=164;n=169) | -4.4 ± 0.37 | -3.1 ± 0.37 |
| Week 2 (n=166;n=163) | -6.3 ± 0.43 | -5.2 ± 0.43 |
| Week 3 (n=157;n=160) | -7.0 ± 0.45 | -5.5 ± 0.45 |
| Week 4 (n=153;n=150) | -8.3 ± 0.46 | -7.0 ± 0.47 |
| Week 5 (n=135;n=130) | -8.4 ± 0.49 | -7.6 ± 0.49 |
| Week 6 (n=122;n=125) | -9.2 ± 0.49 | -8.0 ± 0.49 |
| Week 8 (n=126;n=127) | -9.3 ± 0.56 | -8.0 ± 0.56 |
Responders = YES if subjects achieved a \>= 50% decrease in HAM-A total score from Baseline to respective study week. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; higher score indicates greater anxiety.
| participants | Pregabalin | Placebo |
|---|---|---|
| Week 1 Responder: Yes | 21 | 8 |
| Week 1 Responder: No | 143 | 161 |
| Week 2 Responder: Yes | 39 | 26 |
| Week 2 Responder: No | 127 | 137 |
| Week 3 Responder: Yes | 51 | 23 |
| Week 3 Responder: No | 106 | 137 |
| Week 4 Responder: Yes | 64 | 46 |
| Week 4 Responder: No | 89 | 104 |
| Week 5 Responder: Yes | 58 | 46 |
| Week 5 Responder: No | 77 | 84 |
| Week 6 Responder: Yes | 57 | 48 |
| Week 6 Responder: No | 65 | 77 |
| Week 8 Responder: Yes | 63 | 47 |
| Week 8 Responder: No | 63 | 80 |
| Week 8 (LOCF) Responder: Yes | 84 | 62 |
| Week 8 (LOCF) Responder: No | 93 | 114 |
Participant in remission defined as HAM-A total score of \<= 7. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges 0 - 56; higher score indicates greater anxiety.
| participants | Pregabalin | Placebo |
|---|---|---|
| Week 1 Remission: Yes | 12 | 5 |
| Week 1 Remission: No | 152 | 164 |
| Week 2 Remission: Yes | 22 | 15 |
| Week 2 Remission: No | 144 | 148 |
| Week 3 Remission: Yes | 32 | 18 |
| Week 3 Remission: No | 125 | 142 |
| Week 4 Remission: Yes | 43 | 29 |
| Week 4 Remission: No | 110 | 121 |
| Week 5 Remission: Yes | 39 | 30 |
| Week 5 Remission: No | 96 | 100 |
| Week 6 Remission: Yes | 37 | 32 |
| Week 6 Remission: No | 85 | 93 |
| Week 8 Remission: Yes | 40 | 31 |
| Week 8 Remission: No | 86 | 96 |
| Week 8 (LOCF) Remission: Yes | 55 | 42 |
| Week 8 (LOCF) Remission: No | 122 | 134 |
Time to sustained improvement was defined as time to 50% or greater reduction in HAM-A total score from Baseline, which was sustained for the remainder of the study. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; a higher score indicates greater anxiety.
| days | Pregabalin | Placebo |
|---|---|---|
| Time to Onset of Sustained Hamilton Anxiety Rating Scale (HAM-A) Improvement | 57 (43.0 to 61.0) | — |
Responders = YES using CGI-I if score indicated much improved or very much improved at the last study week. CGI-I is a clinician-rated instrument that measures change in subject's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| participants | Pregabalin | Placebo |
|---|---|---|
| Week 1: Yes | 62 | 49 |
| Week 1: No | 101 | 120 |
| Week 2: Yes | 94 | 74 |
| Week 2: No | 72 | 89 |
| Week 3: Yes | 93 | 76 |
| Week 3: No | 62 | 86 |
| Week 4: Yes | 97 | 88 |
| Week 4: No | 55 | 61 |
| Week 5: Yes | 89 | 81 |
| Week 5: No | 45 | 50 |
| Week 6: Yes | 83 | 76 |
| Week 6: No | 38 | 49 |
| Week 8: Yes | 80 | 82 |
| Week 8: No | 43 | 45 |
| Week 8 (LOCF): Yes | 113 | 110 |
| Week 8 (LOCF): No | 61 | 66 |
CGI-S is a clinician-rated instrument measuring the severity of a subject's symptoms on a 7-point categorical scale. Scores range from 1 (not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill.
| participants | Pregabalin | Placebo |
|---|---|---|
| Normal, not ill at all | 28 | 18 |
| Borderline, mentally ill | 49 | 37 |
| Mildly ill | 49 | 63 |
| Moderately ill | 46 | 48 |
| Markedly ill | 2 | 8 |
| Severely ill | 2 | 1 |
| Among the most extremely ill | 0 | 0 |
| Not assessed | 0 | 1 |
Change: score at each study week minus score at baseline. HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, \& weight loss). Total score ranges from 0 to 52; higher scores indicate more depression.
| score on scale | Pregabalin | Placebo |
|---|---|---|
| Week 1 n=165,168 | -2.1 ± 0.28 | -1.3 ± 0.28 |
| Week 2 n=165,164 | -3.1 ± 0.30 | -2.4 ± 0.31 |
| Week 3 n=156,160 | -3.5 ± 0.32 | -2.8 ± 0.32 |
| Week 4 n=153, 149 | -4.7 ± 0.29 | -3.3 ± 0.29 |
| Week 5 n=135, 130 | -4.3 ± 0.33 | -3.9 ± 0.34 |
| Week 6 n=122, 125 | -4.7 ± 0.33 | -3.8 ± 0.33 |
| Week 8 n= 126, 127 | -4.8 ± 0.40 | -3.8 ± 0.40 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | — | — |
| Placebo | — | — | — |
| Event | Pregabalin | Placebo |
|---|---|---|
| DepressionPsychiatric disorders | 0/180 | 1/176 |
| Abdominal pain upperGastrointestinal disorders | 0/180 | 1/176 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/180 | 1/176 |
| FallInjury, poisoning and procedural complications | 0/180 | 1/176 |
| Cardiac failure congestiveCardiac disorders | 1/180 | 0/176 |
| CellulitisInfections and infestations | 1/180 | 0/176 |
| Chronic Obstructive Pulmonary Disease (COPD)Respiratory, thoracic and mediastinal disorders | 1/180 | 0/176 |
| Event | Pregabalin | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 21/180 | 10/176 |
| HeadacheNervous system disorders | 17/180 | 7/176 |
| SomnolenceNervous system disorders | 15/180 | 6/176 |
| NauseaGastrointestinal disorders | 13/180 | 8/176 |
| Vision blurredEye disorders | 8/180 | 2/176 |
| DiarrheaGastrointestinal disorders | 7/180 | 7/176 |
| SedationNervous system disorders | 7/180 | 7/176 |
| FatigueGeneral disorders | 7/180 | 5/176 |
| NasopharyngitisInfections and infestations | 5/180 | 6/176 |
| Upper respiratory tract infectionInfections and infestations | 3/180 | 6/176 |
| Age, Continuous(years) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Mean | 43.7 ± 11.5 | 43.5 ± 12.5 | 43.6 ± 12.0 |
| Sex: Female, Male(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Female | 129 | 115 | 244 |
| Male | 51 | 61 | 112 |
The record gives a start of Dec 2006, a primary completion of Feb 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Generalized Anxiety Disorder →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →